Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.059 CHF | +0.34% | +7.27% | +43.90% |
04-17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
04-17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Sales 2021 | 331 361.92 28.99K | Sales 2022 | 1.48M 1.61M 129M | Capitalization | 19.96M 21.83M 1.75B |
---|---|---|---|---|---|
Net income 2021 | -11M -12.03M -964M | Net income 2022 | -18M -19.68M -1.58B | EV / Sales 2021 * | - |
Net cash position 2021 | 6.23M 6.82M 546M | Net Debt 2022 | 4.23M 4.63M 371M | EV / Sales 2022 | 16.4 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.61% |
Latest transcript on Spexis AG
1 day | +0.34% | ||
1 week | +7.27% | ||
Current month | -30.59% | ||
1 month | -23.38% | ||
3 months | -80.97% | ||
6 months | -64.24% | ||
Current year | +43.90% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 29/12/21 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 29/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 29/12/21 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 29/12/21 |
Kuno Sommer
BRD | Director/Board Member | 68 | 31/08/12 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.059 | +0.34% | 58,872 |
25/04/24 | 0.0588 | +6.91% | 15,392 |
24/04/24 | 0.055 | -6.78% | 70,500 |
23/04/24 | 0.059 | +2.43% | 166,217 |
22/04/24 | 0.0576 | +4.73% | 158,616 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.90% | 4.36M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- POLN Stock